Predicting liver cancer after hepatitis C cure
Part of Cancer, Digestive system clinical trials.
This study looks at people who have been cured of hepatitis C but still have liver scarring (cirrhosis) to see if certain factors can predict who might develop liver cancer later. It compares those who developed liver cancer with those who did not, to improve future screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have liver scarring (cirrhosis) caused by hepatitis C
- You achieved a sustained virologic response (SVR12) after taking direct-acting antiviral (DAA) medication
- For those who developed liver cancer: you must have been diagnosed with liver cancer by imaging or biopsy on or before June 30, 2025
- For those who did not develop liver cancer: you must have had no liver cancer for at least 36 months after finishing hepatitis C treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
This study asks liver specialists about their views on using non-invasive prediction models to estimate liver cancer risk in hepatitis C patients who have been cured. It aims to understand what helps or prevents them from using these tools.
This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.
This study looks back at medical records of people who had liver cancer (HCC) and had either a transplant or surgery to remove the tumor. It aims to improve a tool that helps predict how well a patient may do, which could guide future treatment decisions.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.